Kornimate/medical-research-clean huggingface dataset:
oncotype dx dcis: impact on radiotherapy decision making

Conditions: Breast Cancer

Summary: prospective single centre study of patients with dcis that have undergone breast conservation surgery.

this is a single centre (royal marsden hospital - chelsea and sutton) non-randomised trial investigating whether the oncotype dx dcis score changes the radiotherapy recommendation made by clinical oncologists in patients with low to moderate risk dcis following breast conserving surgery.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of dcis 2. dcis treated with breast conserving surgery exclusion criteria: 1. prior treatment for dcis or invasive breast cancer in ipsilateral breast. 2. patients with contra-indications to radiotherapy, including prior breast radiotherapy 3. patients who undergo mastectomy for dcis 4. age \< 45 years old 5. patients with \> 25mm dcis 6. patients with multifocal dcis (defined as more than 1 distinct focus of dcis with at least 50mm of intervening benign tissue) 7. patients with invasive (including microinvasion) disease 8. patients with positive axillary nodal disease (including isolated tumour cells) 9. patients with close (\<1mm) or positive radial margins (unless maximally surgically excised or no further dcis on re-excision) 10. patients recommended adjuvant endocrine therapy
porfimer sodium in diagnosing patients with head and neck cancer

Conditions: Head and Neck Cancer

Summary: rationale: drugs that make cancer cells more visible to light may help in the diagnosis of head and neck cancer. purpose: phase ii trial to study the usefulness of porfimer sodium in diagnosing patients with head and neck cancer.

objectives: i. determine whether porfimer sodium fluorescence can be used to reveal early malignant changes in patients with lesions of the oral cavity. ii. investigate whether porfimer sodium fluorescence can define areas of field cancerization in the oral mucosa, specifically satellite foci of malignant cells within the margins of an excision. iii. determine whether uptake of fluorescence is indicative of disease stage. outline: patients receive porfimer sodium iv bolus and are kept in subdued light until examination with a fluorescence photometer 48 hours later. patients must avoid sunlight and other intense lights for an additional 30 days. projected accrual: 20 patients will be accrued per year.

Eligibility criteria:
disease characteristics: malignant or suspected lesions of the head and neck that are scheduled for excisional biopsy lesions no greater than 2 cm in diameter in the mouth, oropharynx, hypopharynx or larynx suspected severe dysplasia, carcinoma in situ and/or invasive carcinoma of the head and neck patient characteristics: age: 18 and over performance status: karnofsky 60-100% life expectancy: not specified hematopoietic: wbc greater than 3500/mm3 platelet count greater than 100,000/mm3 hepatic: sgot and sgpt no greater than 2 times upper limit of normal alkaline phosphatase no greater than 2 times upper limit of normal bilirubin no greater than 2 mg/dl renal: creatinine no greater than 2.5 mg/dl other: no known hypersensitivity to porphyrins not pregnant fertile patients must use effective birth control prior concurrent therapy: not specified

Keywords: stage 0 oropharyngeal cancer stage 0 laryngeal cancer stage 0 hypopharyngeal cancer stage 0 lip and oral cavity cancer stage i lip and oral cavity cancer stage i hypopharyngeal cancer stage i laryngeal cancer stage i oropharyngeal cancer
adherence to antidepressant treatment in subjects with depression

Conditions: Depression

Summary: this study aims to determine whether a combination a first-line antidepressant plus "rt2ck17" in a capsule relative to a first-line antidepressant plus placebo in a capsule results in higher rates of medication adherence in individuals with moderate to severe depression. in this double-blind randomized placebo controlled trial, 100 individuals with a quick inventory of depressive symptomatology-self report (qids-sr) scale score ≥ 14 will be enrolled to participate in an 8 week treatment study. participants will be randomized with a 1-1 ratio to receive 5 milligrams (mg) "rt2ck17" + 10 mg escitalopram or placebo + 10 mg escitalopram to be taken orally once per day. participants will undergo a 3 hour baseline evaluation visit at week 0, two 30-minute office visits (week 2 and 4), one 60-minute office visit (week 8) and three 5-minute phone calls (weeks 1, 3, and 6) during which clinical assessments and measures will be obtained. the trial is designed with two stages: 20 participants in stage 1 will be used to estimate the adherence effect size; stage 2 is designed with an interim analysis to test our hypotheses.


Eligibility criteria:
inclusion criteria: * baseline qids-sr ≥ 14 (moderate depression) * age 18 - 65 * written informed consent * major depressive disorder, single-episode/recurrent, not in remission exclusion criteria: * rt2ck17-related exclusions * uncontrolled hyperthyroidism * glaucoma * motor tics * monoamine oxidase inhibitor treatment * serious coronary artery disease, cardiomyopathy, serious cardiac arrhythmias * uncontrolled hypertension * peripheral vasculopathy * pregnancy * bipolar disorder * psychotic disorder * history of intolerability of study medications * currently taking psychiatric medications * current substance use disorder (other than nicotine) * current alcohol use disorder
evaluation of therapeutic effects of led (627 +/- 10nm) the initial phase of the ankle sprains treatment

Conditions: Ankle Sprain

Summary: the purpose of this study is to evaluate the therapeutic effects of the led (627 +/- 10 nm) with respect to the localized pain and local swelling of ankle sprains in the initial phase.

a variety of therapies for the treatment of sprains has emerged as they occur advances in technological applications. therapy with coherent and non-coherent light is a treatment modality for a variety of musculoskeletal injuries. the main benefits certificates for phototherapy are the reduction of nociceptive processes, tissue remodeling, among others. the aim of the present paper is to analyze the changes caused by the use of led (627 +/- 10 nm) with an energy density of 10 j / cm2 in 40 subjects divided into two groups (placebo and led). all volunteers participating in this study had ankle inversion sprain grade ii treated with the price technique. the study was performed in six days. and the results were verified by review of all individuals, through the visual analogue scale (vas) of pain, mcgill pain questionnaire and titrimetry. measurements were performed at first, third and sixth day's of treatment.

Eligibility criteria:
inclusion criteria: * active individuals * with medical referral * with clinical diagnosis of inversion sprain grade ii * the day he suffered the injury * without prescriptions exclusion criteria: * individuals who had previous trauma and orthopedic disorders such as fractures, tendinopathy, previous surgical procedure * other systemic diseases.

Keywords: laser led price pain edema
the sleep and teamwork in ems study

Conditions: Fatigue; Sleep

Summary: more than half of emergency medical services (ems) workers report work-related mental and physical fatigue. odds of injury among fatigued ems workers are nearly double that of non-fatigued workers. there is a compelling need to reduce fatigue among ems workers, yet few ems organizations have a formal fatigue management program and many may not be cost-effective or evidence-based. this trial addresses national goals of the national occupational research agenda (nora) and tests a novel approach to fatigue risk management that is easily scalable to large workforces and low-cost for employers of shift workers.

the investigators will test an enhanced version of our sleeptracktxt pilot intervention - sleep and fatigue treatment in ems (saftie) - in a two-arm parallel cluster-randomized design of ems agencies. our unit of randomization will be the ems agency, with the intervention deployed as a fatigue risk management program that can be integrated into an agency's existing program. during the active intervention phase, the investigators will use saftie and an attention placebo control (apc) group to test the specific effect of our multi-component intervention on ems worker fatigue and sleep health.

Eligibility criteria:
inclusion criteria: * 18 years or older * live in united states (including hawaii and alaska) * licensed / certified ems clinician * currently work in shifts * do at least one clinical shift per week * own a smartphone * willing to answer monthly surveys and daily text-messages, exclusion criteria: * exclude ems personnel who are primarily administrative with non-clinical duties * are restricted from using personal smartphone during periods of work * do not own a smartphone capable of running the study mobile app
a study of prevalence of her3 expression in non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: there is currently a lack of published her3 expression prevalence data among non-small cell lung cancer (nsclc) patients. the estimation of her3 expression prevalence in this population using archival tissue samples and the assessment of associated patient characteristics in real world (rw) data will ultimately inform clinical strategy and increase awareness among health care providers (hcps) and the greater medical community to improve patient care.

the purpose of this study is to use archival tissue samples and rw data to generate her3 expression prevalence data within the nsclc population and by patient characteristics (e.g., ethnicity, histology, smoking status, age, prior treatment, etc.). the primary objective of the study will analyze and assess archival tissue specimens and associated rw data to: * increase the understanding of her3 expression in nsclc among hcps and the medical community * generate evidence to support future clinical strategies in this area

Eligibility criteria:
inclusion criteria: * age ≥18 years in us * histologically or cytologically documented advanced or metastatic nsclc * at least one sample available and evaluable for her3 expression additional population-specific inclusion criteria: for cohort 1: * tissue sample collected on or after january 1, 2013 for cohort 2: * egfrm nsclc previously treated with a 3rd generation egfr tki * 2 samples are available and evaluable for her3 expression at 2 timepoints: one pre-treatment and one post-treatment, where the treatment is a 3rd generation tki (defined as osimertinib, aumolertinib \[formerly almonertinib\]) for cohort 3: * alk+ nsclc * 2 samples are available and evaluable for her3 expression at 2 timepoints: one pre-treatment and one post-treatment, where the treatment is a tki for cohort 4: * nsclc harboring a kras p.g12c mutation or egfr exon 20 insertion * 2 samples are available and evaluable for her3 expression at 2 timepoints: one pre-treatment and one post-treatment exclusion criteria: * prior treatment with an anti-her3 antibody or topoisomerase i inhibitor (single-agent or combination) * prior treatment with an antibody drug conjugate (adc) that contains a topoisomerase i inhibitor * previous histologic or cytologic evidence of small cell or combined small cell/non-small cell disease

Keywords: non-small cell lung cancer her3 expression prevalence archival tissue samples real-world data
viral and microbial circulation between humans, domesticated and wild animals along an ecotone, democratic republic of congo

Conditions: Zoonotic Disease

Summary: this study will evaluate the overlap between the intestinal microbiome and virome of wild and domesticated animals and human beings living in close proximity in three sites along an ecotone (ecological gradient) in the democratic republic of congo.

the microtone study sheds light on zoonotic disease emergence by examining social and ecological pathways facilitating microbial and viral flows between people and selected wild and domesticated animals along a gradient of ecological change in a forest-savanna mosaic in the democratic republic of congo, an epicenter of zoonotic disease emergence. the investigators analyze potential viral and bacterial overlap among humans and animals and explain this overlap (or not) through social sciences and ecological analyses of human and animal mobilities, practices and contacts. this multi-disciplinary, multi-species investigation in an ecotone (a transitional ecological zone linked to zoonotic disease emergence) offers a "pre-history" of spillover and emergence, tracing an ecological zeb of virome and microbial sharing among humans and animals. it will elucidate why such microbial and viral flows occur. to conduct this investigation,there are two human sub-studies: the social sciences participatory study; and the clinical study. the clinical study will involve 30 human subjects from whom blood and stool samples will be collected. the social sciences participatory study will involve self-collected activity and animal contact data and oral interviews among 60 human subjects.

Eligibility criteria:
inclusion criteria: * age 18 years or older * accept participation in study * residing in one of three villages selected * in good health and able to conduct habitual daily activities * accept self-collection of 2g of stool * accept blood collection (2-2.5 ml) by a medical professional * accept to self-collect daily activities and contacts with selected wild and domesticated animals for five months * accept to participate in an anthropological-historical interview on changing practices and contacts with wild and domesticated animals exclusion criteria: * vulnerable adults will not be included * women who are pregnant or nursing at the time of recruitment and inclusion will not be included. * adults declaring themselves ill and unable to conduct their habitual daily activities will not be included. * adults with a chronic illness will not be included * adults who have a family member already included in the study will not be included. * adults refusing either recording of interviews or note-taking during interviews will not be included.

Keywords: microbiome virome zoonotic disease ecological gradient human-animal relations anthropology social sciences
the effect of terlipressin in the prevention of type 2 hepatorenal syndrome by improving mean arterial pressure

Conditions: Hepatorenal Syndrome

Summary: appreciation of the central role for arterial vasodilatation in the pathogenesis of hepatorenal syndrome (hrs) has led to routine use of vasoconstrictors in combination with albumin as a medical therapy for hrs. terlipressin have been explored but the optimal approach for such therapies has not yet been established. as compared with albumin, treatment with terlipressin and albumin is effective in improving renal function in patients with cirrhosis and hepatorenal syndrome. our previous study showed that mean arterial pressure (map) is a predictor of hepatorenal syndrome occurrence in cirrhotic patients with ascites. the purpose of this study was to examine the role of targeting an early and substantial increase in mean arterial pressure in the prevention of type 2 hrs.


Eligibility criteria:
inclusion criteria: 1. cirrhosis as diagnosedby liver biopsy or clinical, biochemical, ultrasound,and/or endoscopic findings; 2. type 2 hrs with a map decrees for at least 10mmhg compared to basal blood pressure ; 3. age 18 to65 years; 4. absence of severe bacterial infection associated with findings of systemic inflammatory response as diagnosedby the presence of at least 2 of the following criteria: body temperature \ 38°c, heart rate \>90 beats/min, respiration rate\>20/min, and white-cell count \ 12 x106/l or \>6% of band forms; patients with bacterial infections, however, could be included in the study if renal failure persisted after infection resolution; 5. the absence of cardiovascular diseases and any extra hepatic disease that could affect the short-term prognosis; 6. the absence of findings suggestive of organic nephropathy; 7. the absence of advanced hepatocellularcarcinoma. exclusion criteria: 1. patients with history of coronary artery disease 2. cardiomyopathy 3. ventricular arrhythmia 4. obstructive arterial disease of limbs -

Keywords: terlipressin mean arterial pressure type 2 hrs
effect of guided imagery on chemotherapy-related nausea and vomiting

Conditions: Chemotherapy-induced Nausea and Vomiting; Pediatric Cancer

Summary: the goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric oncology patients. participants will receive either guided imagery+routine care or routine care. the researchers will compare nausea and vomiting and vital signs between groups.

despite significant advances in anti-emetic treatment, chemotherapy induced nausea and vomiting (cinv) is considered a major side-effect that significantly reduces the quality of life of children diagnosed with cancer. guided imagery is one of the methods of distraction that allows the individual to go to an environment or scene that will make the individual comfortable, peaceful, happy, and focused. in this study, the participants will be randomized in a single blind manner (participant) to either intervention or control groups.

Eligibility criteria:
inclusion criteria: * 7 to 18 years old, * who will receive intravenous chemotherapy, * no cognitive or neurological disease that would prevent communication, * receiving a chemotherapy protocol with a high or moderate emetogenic effect according to the mascc/esmo antiemetic guideline classification, * no verbal, visual and auditory communication disabilities (ability to speak turkish, no mental deficiency), * children whose parents and themselves volunteered to participate in the study exclusion criteria: * children receiving radiotherapy, * taking ginger powder or vitamins to reduce nausea, * children who did not want to participate in the study
a cross-sectional study of congenital cytomegalovirus infection in newborns in china

Conditions: Congenital Cytomegalovirus Infection

Summary: the primary objectives of this study were to evaluate the incidence of congenital cmv infection in neonates, and assess the concordance of detecting congenital cytomegalovirus (cmv) infection in neonatal saliva and urine samples.

this cross-sectional study was conducted to recruit neonates less than 14 days old delivered in maternal and child health hospitals (mchhs) of xinmi city, jiaxian county, zhongmu county and huli district xiamen city, in china, from june 2015 to june 2016. the aim of this study is to enroll \~1800 neonates, and collect their saliva and urine samples which will be tested the cmv dna by using real-time pcr.

Eligibility criteria:
inclusion criteria: * neonates aged 0 to 14 days * neonates delivered in mchhs of xinmi city, jiaxian county, zhongmu county and huli district xiamen city exclusion criteria: * the parents of neonates not comply with our study

Keywords: cytomegalovirus
tooth wear:m tooth wear : diagnosis- treatment decision

Conditions: Dental Wear

Summary: tooth wear is a physiological process occurring from normal functioning of the dentition throughout lifetime.

the studies in the current literature indicated that both techniques of tooth preparation and the materials used are appropriate for the treatment of this condition, but the tendency is to reduce tooth preparation as reasonably possible. in this clinical trial, the investigators will compare the outcomes of direct resin composite and indirect polymer-infiltrated-ceramic-network.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older, in good general health, willing to participate in the study and accepting to come to regular controls in the future. * patients representing any type of significant tooth wear (≥ 1 mm depth) with dentine exposure in at least 4 teeth: localized tooth wear anterior or posterior teeth and generalized tooth wear anterio and posterior teeth. * patients having posterior support with at least 4 molars in occlusion, 1 pair per side, excluding third molar. exclusion criteria: * patients wearing removable partial prosthesis * patients presenting skeletal cl iii occlusal relationship * patients with remaining clinical crown of ≤ 3 mm in height and presenting tooth anomaly in shape and number in addition to anterior diastemas. * patients with symptomatic temporomandibular joint disorders.
prostatic size reduction following of leuprorelin acetate

Conditions: Prostate Cancer Adenocarcinoma; Prostate Adenocarcinoma

Summary: to determine the possible reduction in prostate size following the administration of leuprelin prior to the application of radiotherapy.

prostate cancer (pc) is the most common tumor in men worldwide, including our country, with an incidence of 34,413 cases in 2020 (70.6 per 100,000 inhabitants) . the elevation of prostate-specific antigen (psa) in blood and/or an abnormality in rectal examination necessitate a prostate biopsy, the diagnostic procedure involving the extraction of a small prostate tissue sample for microscopic analysis and classification of cancer cells according to the gleason scale (malignancy grade). once diagnosed, extension studies (thoraco-abdominal ct, bone scintigraphy, pet choline, etc.) are conducted to rule out metastasis, the spread of tumor cells originating in the prostate, to other organs. the majority of pc cases are diagnosed at localized stages (without distant disease), allowing for local curative treatments such as surgery (prostatectomy) and radiation therapy (prostate radiotherapy). hormonal androgen blockade (hab) combined with radiation therapy improves oncological outcomes for localized pc . additionally, hab administered before radiation therapy results in a reduction in prostate gland size . this reduction allows for a decrease in the volume to be irradiated, leading to lower toxicity on surrounding healthy tissues and organs (primarily the bladder and rectum). this apparent volume reduction is expected two months after initiating hab, typically coinciding with the simulation ct scan for radiotherapeutic treatment planning. however, there are no studies certifying or quantifying this reduction and its subsequent benefits in pc treatment. currently, comparing prostate size pre- and post-hab is challenging. the first measurement is obtained from ultrasound and/or mri at the time of diagnosis, while the second measurement (post-hab) is only taken during radiotherapist oncologist planning ct. this poses two problems: the inadequacy of comparing prostate sizes between different tests, and potential discrepancies in prostate delineation due to variations among different participating radiation oncologists.

Eligibility criteria:
inclusion criteria: man with prostate positive biopsy. able to ssgned informed consent form. need of hormonal treatment before start of radiotherapy exclusion criteria: patients with prostate size of less than 20 cc at diagnosis. patients with positive lymph nodes or metastatic prostate cancer disease on imaging studies. patients with previous pelvic radiation therapy.

Keywords: reduccion eligard leupreline radiotherapy feltes